New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched…
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) --…
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June…
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,…
Scope of the SESHAT Project at Pioneering Hospital, Part of the Catalan Health Institute, Includes Deployment of up to 1,000…
Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) with its Cosmo Intelligent…
Promising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of…
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a…
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and…
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved…